- Home
- ME vs STTK Comparison
ME vs STTK Comparison
Compare ME & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- STTK
- Stock Information
- Founded
- ME 2006
- STTK 2016
- Country
- ME United States
- STTK United States
- Employees
- ME N/A
- STTK N/A
- Industry
- ME Precision Instruments
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ME Health Care
- STTK Health Care
- Exchange
- ME Nasdaq
- STTK Nasdaq
- Market Cap
- ME 168.9M
- STTK 173.6M
- IPO Year
- ME N/A
- STTK 2020
- Fundamental
- Price
- ME $0.34
- STTK $3.69
- Analyst Decision
- ME Hold
- STTK Strong Buy
- Analyst Count
- ME 1
- STTK 3
- Target Price
- ME $0.47
- STTK $10.67
- AVG Volume (30 Days)
- ME 2.3M
- STTK 122.7K
- Earning Date
- ME 11-06-2024
- STTK 11-07-2024
- Dividend Yield
- ME N/A
- STTK N/A
- EPS Growth
- ME N/A
- STTK N/A
- EPS
- ME N/A
- STTK N/A
- Revenue
- ME $199,188,000.00
- STTK $4,123,999.00
- Revenue This Year
- ME $0.05
- STTK $164.45
- Revenue Next Year
- ME $17.98
- STTK N/A
- P/E Ratio
- ME N/A
- STTK N/A
- Revenue Growth
- ME N/A
- STTK 380.09
- 52 Week Low
- ME $0.29
- STTK $1.33
- 52 Week High
- ME $1.10
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- ME 52.64
- STTK 51.49
- Support Level
- ME $0.29
- STTK $3.63
- Resistance Level
- ME $0.32
- STTK $3.94
- Average True Range (ATR)
- ME 0.02
- STTK 0.23
- MACD
- ME 0.01
- STTK 0.06
- Stochastic Oscillator
- ME 88.47
- STTK 56.14
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.